- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.05. | Leerink startet Coverage für Atrium Therapeutics mit "Outperform" | 2 | Investing.com Deutsch | ||
| ATRIUM THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15.05. | Leerink initiates Atrium Therapeutics stock with outperform rating | 1 | Investing.com | ||
| 15.05. | Atrium Therapeutics, Inc. reports Q1 results | 1 | Seeking Alpha | ||
| 14.05. | Atrium Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.05. | Atrium Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.05. | Atrium Therapeutics Reports First Quarter 2026 Financial Results | 475 | PR Newswire | SAN DIEGO, May 14, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company... ► Artikel lesen | |
| 23.04. | Kooperation mit Bristol Myers Squibb: Atrium Therapeutics sichert sich Meilensteinzahlung von 15 Mio. US-Dollar | 24 | Investing.com Deutsch | ||
| 23.04. | Atrium Therapeutics earns $15M from Bristol Myers Squibb | 5 | Investing.com | ||
| 23.04. | Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration | 301 | PR Newswire | SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics... ► Artikel lesen | |
| 17.04. | Atrium Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 02.03. | Novartis spaltet Atrium Therapeutics aus Avidity-Übernahme ab | 30 | transkript.de | ||
| 01.03. | Atrium Therapeutics Launches With $270M for RNA Therapies Addressing Rare Cardio Conditions | 7 | MedCity News | ||
| 27.02. | Atrium Therapeutics spins out of Avidity, aiming to target rare heart diseases with RNA | 8 | BioPharma Dive | ||
| 27.02. | Atrium Therapeutics arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates | 6 | FierceBiotech | ||
| 27.02. | Atrium Therapeutics Launches with $270M | 2 | Contract Pharma | ||
| 27.02. | Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies | 1.017 | PR Newswire |
Spinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform
Lead candidates ATR 1072... ► Artikel lesen | |
| 26.02. | Atrium Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.02. | Atrium Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 22,430 | +0,49 % | Unterbewertet - Analysten rücken LifeScience in den Fokus! Bayer, Vidac Pharma, Novo Nordisk und Pfizer im Check | Dass Analysten den LifeScience-Bereich zuletzt wieder besser einschätzen, zeigt die dynamische Kursziel-Anpassung der DZ Bank für Bayer. Der starke Jahresstart des Pharma- und Agrarchemiekonzerns führt... ► Artikel lesen | |
| GILEAD SCIENCES | 116,12 | +0,31 % | Gilead Gets Positive CHMP Opinion For Trodelvy In First-Line Metastatic TNBC | FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD) on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended marketing authorization for Trodelvy... ► Artikel lesen | |
| TEVA | 29,700 | +1,02 % | Teva: European Medicines Agency Accepts Marketing Authorization Application For TEV-'749 | PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals International GmbH, a unit of Teva Pharmaceutical Industries (TEVA), and Medincell announced that the European Medicines Agency has accepted the... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 376,10 | +0,44 % | Vertex Announces New Drug Submission for Suzetrigine Has Been Accepted for Review by Health Canada for the Treatment of Moderate-to-Severe Acute Pain in Adults | ||
| VIATRIS | 14,610 | +1,87 % | Dividendenbekanntmachungen (22.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 3M COMPANY US88579Y1010 0,78 USD 0,6712 EUR ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,0645 EUR ADVANCED ENERGY INDUSTRIES... ► Artikel lesen | |
| EYEPOINT | 11,200 | +0,90 % | EyePoint, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | ||
| BAUSCH HEALTH | 4,610 | -2,29 % | Bausch Health Companies Inc.: Bausch Health Announces 2026 Annual Meeting of Shareholder Results | LAVAL, QC, May 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 64,88 | 0,00 % | Ionis, Alnylam, BioMarin up as Citi starts at Buy on catalyst and growth outlook | ||
| ASSEMBLY BIOSCIENCES | 25,050 | +2,66 % | Assembly Biosciences, Inc.: Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases | - Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 -- Builds on completed Phase 1a study and ongoing development in HDV - SOUTH SAN FRANCISCO... ► Artikel lesen | |
| ALNYLAM PHARMACEUTICALS | 259,50 | +1,21 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 18.05.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 58,26 | +1,53 % | Nektar Therapeutics Reports First Quarter 2026 Financial Results | SAN FRANCISCO, May 7, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2026.
Cash... ► Artikel lesen | |
| FILANA THERAPEUTICS | 1,160 | +3,02 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q1 2026 Financial Results and Business Update | AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| AMARIN | 12,200 | -2,40 % | Amarin Corporation plc: Amarin Reports 2026 First Quarter Financial Results | Total Revenue Increased Led by Higher International Sales Generated Positive Cash Flow and Reiterates Expectation for Full Year Positive Cash Flow Recently Updated Industry Guidelines Expand Global... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 3,690 | +7,42 % | ORAMED PHARMACEUTICALS INC. - 10-Q, Quarterly Report | ||
| AXSOME THERAPEUTICS | 205,90 | +1,28 % | XFRA 19X: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
ATRIUM THERAPEUTICS INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell -0,08 % bei einem Aktienkurs von 13,080 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ATRIUM THERAPEUTICS INC finden Sie auf Wallstreet Online.